Delivery Order SPE2DB22D2103-SPE2DB25FR9SM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,375.65 with a firm fixed price structure. This non-set-aside contract, awarded on August 18, 2025, with completion scheduled for August 19, 2025, represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.60 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector (0.5 ml). This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $1,681.90 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector pharmaceutical product. The contract was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, utilizing firm fixed-price pricing with no set-aside designation. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with a completion date of July 31, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,323.55 to AmerisourceBergen Drug Corp for the supply of Xyosted 75 mg/0.5 mL auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is unset-aside and represents a child order under a larger vehicle supporting...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a small-value pharmaceutical procurement fulfilled through performance in Conshohocken, Pennsylvania. The award was made competitively with no set-aside designation and is classified as a child contract under a larger...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9SMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,425.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector pharmaceutical products. This firm fixed price, competitively awarded delivery order was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company's extensive portfolio of federal contract awards with the DLA Medical Supply Chain demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains. This delivery order reflects the company's ongoing role in fulfilling DLA's pharmaceutical support requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its prime vendor arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/25/25 |